|
rs1057519919
|
MYCN;MYCNOS
|
Adenocarcinoma of pancreas
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs1057519919
|
MYCN;MYCNOS
|
Malignant Uterine Corpus Neoplasm
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs1057519919
|
MYCN;MYCNOS
|
NEUROBLASTOMA, SUSCEPTIBILITY TO
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs1057519919
|
MYCN;MYCNOS
|
Glioblastoma
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs1057519919
|
MYCN;MYCNOS
|
Medulloblastoma
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs113994115
|
MYCN;MYCNOS
|
FEINGOLD SYNDROME 1
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs121913667
|
MYCN;MYCNOS
|
Oculodigitoesophagoduodenal syndrome
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1553370260
|
MYCN;MYCNOS
|
Duodenal atresia
|
ACTCG |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1553370260
|
MYCN;MYCNOS
|
FEINGOLD SYNDROME 1
|
ACTCG |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1553370260
|
MYCN;MYCNOS
|
Microcephaly (physical finding)
|
ACTCG |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1553370260
|
MYCN;MYCNOS
|
Small anterior fontanelle
|
ACTCG |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1558534266
|
MYCN;MYCNOS
|
FEINGOLD SYNDROME 1
|
GC |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1200941109
|
MYCN;MYCNOS
|
Neuroectodermal Tumor, Primitive
|
|
0.010 |
GeneticVariation |
BEFREE |
H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?
|
23354654 |
2013 |
|
rs1200941109
|
MYCN;MYCNOS
|
Central Nervous System Embryonal Tumor, Not Otherwise Specified
|
|
0.010 |
GeneticVariation |
BEFREE |
Multiplex ligation-dependent probe amplification analysis revealed PDGFR-alpha amplification and EGFR gain in two cases and N-Myc amplification in one case of H3.3 G34R mutated CNS-PNET.
|
23354654 |
2013 |
|
rs1200941109
|
MYCN;MYCNOS
|
Glioblastoma
|
|
0.010 |
GeneticVariation |
BEFREE |
The K27M (AAG → ATG, lysine → methionine) mutation was found in 33 glioblastomas (26 %); the G34R (GGG → AGG, glycine → arginine) was observed in 6 glioblastomas (5.5 %).
|
23354654 |
2013 |
|
rs1200941109
|
MYCN;MYCNOS
|
Brain Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, because pediatric patients with glioblastoma and CNS-PNET are treated according to different therapeutic protocols, these findings may raise further concerns about the reliability of the histological diagnosis in the case of an undifferentiated brain tumor harbouring G34R H3.3 mutation.
|
23354654 |
2013 |
|
rs57961569
|
MYCN;MYCNOS
|
Neuroblastoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Stratified analysis revealed that rs579</span>61569 GG carriers were more likely to develop neuroblastoma in the following subgroups: children older than 18 months, tumor derived from the adrenal gland, and clinical stages III + IV.
|
29997440 |
2018 |
|
rs57961569
|
MYCN;MYCNOS
|
Central neuroblastoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Stratified analysis revealed that rs579</span>61569 GG carriers were more likely to develop neuroblastoma in the following subgroups: children older than 18 months, tumor derived from the adrenal gland, and clinical stages III + IV.
|
29997440 |
2018 |
|
rs57961569
|
MYCN;MYCNOS
|
Childhood Neuroblastoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Stratified analysis revealed that rs579</span>61569 GG carriers were more likely to develop neuroblastoma in the following subgroups: children older than 18 months, tumor derived from the adrenal gland, and clinical stages III + IV.
|
29997440 |
2018 |
|
rs57961569
|
MYCN;MYCNOS
|
Childhood Kidney Wilms Tumor
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, in the stratification analysis, the rs57961569 was found to be associated with decreased Wilms tumor susceptibility in the children older than 18 months (AOR = 0.65, 95% CI = 0.42-1.00, P = .050).
|
31343784 |
2019 |
|
rs57961569
|
MYCN;MYCNOS
|
Nephroblastoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, in the stratification analysis, the rs57961569 was found to be associated with decreased Wilms tumor susceptibility in the children older than 18 months (AOR = 0.65, 95% CI = 0.42-1.00, P = .050).
|
31343784 |
2019 |
|
rs772399455
|
MYCN;MYCNOS
|
Carcinogenesis
|
|
0.010 |
GeneticVariation |
BEFREE |
Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
|
24213573 |
2014 |
|
rs772399455
|
MYCN;MYCNOS
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation |
BEFREE |
Transgenic expression of activated Kras(G12D) in mouse respiratory epithelium is sufficient to induce lung adenocarcinomas; however, transcriptional mechanisms regulated by K-Ras during the initiation of lung cancer remain poorly understood.
|
24213573 |
2014 |
|
rs772399455
|
MYCN;MYCNOS
|
Lung Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo.
|
24213573 |
2014 |
|
rs772399455
|
MYCN;MYCNOS
|
Adenocarcinoma of lung (disorder)
|
|
0.010 |
GeneticVariation |
BEFREE |
Transgenic expression of activated Kras(G12D) in mouse respiratory epithelium is sufficient to induce lung adenocarcinomas; however, transcriptional mechanisms regulated by K-Ras during the initiation of lung cancer remain poorly understood.
|
24213573 |
2014 |